HIF1A and pancreatic neoplasm: Indeed, gemcitabine resistance is associated with EMT and induction of HIF-1α in pancreatic cancer cells (Wang et al. 2014), leading to the pharmacologic manipulation of HIF-1α as novel therapeutic approach to overcome resistance.